文献速递肿瘤 PET/CT放射性药物与辐射防护

全身定量成像PET/CT性能要求的标准化:一项国际提案

Standardization of PET/CT Performance Requirements for Whole-Body Quantitative Imaging: An International Proposal.
PubMed 文献 · J Nucl Med · 2025-10-01

目前临床试验中PET扫描仪验证体模、方法和验收标准尚未标准化,导致许多扫描仪因不同试验被多次测试。本文综述EARL、CTN和澳大利亚新西兰学会的验证项目,提出标准化PET扫描仪验证范式,包括18F每季度校准验证、其他核素每年校准验证,以及±5%(18F)和±10%(其他核素)的验收标准。

要点

  • 建议18F校准每季度验证一次,其他核素每年校准一次。
  • 建议18F校准准确度±5%,其他核素±10%作为验收标准。
  • 建议使用NEMA NU2图像质量体模或CTN5体模在8:1靶本比下每年验证EARL 2一致性恢复系数性能。

核心结论

  • 提出了一套国际标准化的PET扫描仪验证范式,国际采用并结合数据共享系统有望为临床试验创造更高效、稳健、统一和可信的扫描仪验证环境,同时提高临床试验资格认定效率、降低成本并减少重复测试。

研究设计与样本

  • 本文为国际提案,详细综述了欧洲核医学研究有限公司(EARL)、核医学与分子影像学会临床试验网络(CTN)以及澳大利亚新西兰核医学学会澳大利亚放射性药物试验网络目前执行的PET扫描仪验证项目,以识别异同、优势和不足。

主要发现

  • 体模要求、采集、重建、分析和验收标准均已制定,与当前标准扫描仪验证方法合理对齐,并在发现项目差异处提出了改进和澄清建议。
  • 提出基于放射性核素特异性扫描仪校准和协调恢复系数性能测量的扫描仪验证项目。
  • 建议18F校准每季度验证一次,其他核素每年校准一次。
  • 提出18F校准准确度±5%、其他核素±10%作为验收标准。
  • 建议使用美国电气制造商协会NU2图像质量体模或CTN5体模在8:1靶本比下每年验证EARL 2一致性恢复系数性能,但建议采用对比度恢复系数而非恢复系数。

关键数值与推荐

  • 18F校准验证频率:每季度一次。
  • 其他核素校准验证频率:每年一次。
  • 18F校准准确度验收标准:±5%。
  • 其他核素校准准确度验收标准:±10%。
  • 年度恢复系数性能验证:使用NEMA NU2图像质量体模或CTN5体模,靶本比8:1,建议采用对比度恢复系数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Currently, PET scanner validation phantoms, methods, and acceptance criteria for clinical trials are not standardized. This situation generates substantial inefficiencies with many scanners being tested multiple times for different trials. Herein we propose a standardized PET scanner validation paradigm for clinical trials. Methods: At present, active PET scanner validation programs administered by the European Association of Nuclear Medicine Research Ltd. (EARL), the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network (CTN), and Australia New Zealand Society of Nuclear Medicine Australasian Radiopharmaceutical Trials Network are reviewed in detail to identify similarities, differences, strengths, and weaknesses. PET criteria that help define the quantitative performance characteristics most critical for clinical trials are identified. Historical quantitative scanner performance capabilities are reviewed, including increasing availability of primary and secondary standard activity measurements for calibration purposes. Methodologies for these phantom-based measurements are reviewed, and standardized approaches are recommended. Results: Phantom requirements, acquisitions, reconstruction, analysis, and acceptance criteria have all been developed to be reasonably aligned with current standard scanner validation approaches, while at the same time recommending improvements and clarifications where programmatic differences were identified. A scanner validation program based on the measurement of radionuclide specific scanner calibration and harmonized recovery coefficient performance is proposed. Quarterly calibration verification of 18F and annual calibration of other radionuclides are recommended. Accuracy of ±5% for 18F calibration and ±10% for other radionuclides are proposed acceptance criteria. Annual verification of EARL 2-concordant recovery coefficient performance using a National Electrical Manufacturers Association NU2 image quality phantom or CTN5 phantom imaged at an 8:1 target-to-background contrast is recommended, although contrast recovery coefficients, rather than recovery coefficients, are advised. Conclusion: An internationally standardized PET scanner validation paradigm is proposed. International adoption of such a system combined with a data-sharing system would create a more efficient, robust, uniform, and trustworthy scanner validation environment for clinical trials while improving clinical trial qualification efficiency, decreasing costs and mitigating duplication of testing.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sunderland JJ, Boellaard R, Dickson JC, et al. Standardization of PET/CT Performance Requirements for Whole-Body Quantitative Imaging: An International Proposal. J Nucl Med. 2025. PMID: 40610229. doi:10.2967/jnumed.124.269349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。